Advertisement

Volume 133, Issue 9

 

 

February 28, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Novel mechanism for upregulation of cyclins in MCL. See the article by Martín-Garcia et al.

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
In a plenary paper, the investigators describe the high efficacy and safety of the anti–complement C1s humanized monoclonal antibody sutimlimab in the therapy of cold agglutinin disease, a new breakthrough in the management of this often-challenging autoimmune hemolytic anemia.


Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
The investigators describe the in vitro and in vivo efficacy of a novel small molecule that induces the selective degradation of Bruton tyrosine kinase (BTK), IKZF1, and IKZF3, 3 proteins that are critical for the survival of many B-cell malignancies.


The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma
This paper presents a new World Health Organization provisional entity of MYC-negative Burkitt-like lymphoma with 11q aberrations (mnBLL, 11q,) that is distinct from MYC-positive sporadic Burkitt lymphoma, other germinal center–derived B-cell lymphomas, and diffuse large B-cell lymphoma.


Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT
These investigations show that fibronectin, an abundant plasma protein synthesized by the liver, modulates the key interactions involved in the pathogenesis of heparin-induced thrombocytopenia. The findings are of notable clinical significance.


Bad weed: synthetic cannabinoid–associated coagulopathy
This Blood Spotlight brings attention to clinically relevant aspects of the current epidemic of coagulopathies associated with the use of synthetic cannabinoids.


Thromboinflammation: challenges of therapeutically targeting coagulation and other host defence mechanisms
This review article covers a broad array of contributing factors and therapeutic interventions in the treatment of thromboinflammatory conditions.


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.